Verified· 2 sources

Micreos GmbH

Summary

About the company

Micreos GmbH is a platform biotech company focused on the discovery and development of recombinant proteins for chronic dermatology conditions. The company develops engineered endolysin therapeutics that target pathogens such as Staphylococcus aureus, with its lead molecule MEndoB being developed for use in atopic dermatitis and showing preclinical data on safety, efficacy and low propensity for resistance.

AI-generated

Offering

Products & services

Industry:Research & Development

✓ Offered2

Engineered Endolysin Platform

Engineered endolysins to selectively eliminate disease-driving bacterial pathogens while preserving the healthy microbiome; developed as precision biologics for dermatology, oncology, infectious diseases and other therapeutic areas.

Atopic Dermatitis Therapy Program

Selective treatment of Staphylococcus aureus in atopic dermatitis; developed to specifically reduce pathogenic bacteria and restore the skin microbiome.

Outbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub

Micreos GmbH

About the company

Products & services

Looking for direct email addresses and phone numbers?

Micreos GmbH

About the company

Products & services

Looking for direct email addresses and phone numbers?

No knowledge articles yet

Micreos GmbH in comparison

Industry comparisons are coming soon

Similar companies